Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan

NCT03672097 is registered in ClinicalTrials.gov with Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company as lead sponsor.

NCT NCT03672097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03672097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan
Lead sponsor
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Phase
Phase 4
Overall status
Completed
Start date
October 16, 2018
Completion date
August 19, 2020
Enrollment
204 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome (acs)